Akash Tewari
Stock Analyst at Jefferies
(4.79)
# 575
Out of 4,696 analysts
506
Total ratings
60.7%
Success rate
14.2%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QW0 argenx SE | Maintained: Buy | n/a | $912.60 | - | 6 | Sep 3, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,350 → $1,440 | $1,160.08 | +24.13% | 46 | Sep 1, 2026 | |
| LTGO Latigo Biotherapeutics | Initiated Coverage: Buy | $50 | $21.77 | +129.67% | 1 | Sep 1, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $104 → $105 | $66.97 | +56.79% | 39 | Aug 31, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $138 | $103.81 | +32.94% | 39 | Aug 20, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $610 → $633 | $556.75 | +13.70% | 4 | Aug 11, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $50 | $28.18 | +77.43% | 2 | Aug 11, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $40 → $48 | $21.40 | +124.30% | 3 | Aug 11, 2026 | |
| PFE Pfizer | Maintained: Buy | $34 | $29.02 | +17.16% | 45 | Aug 5, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $200 | $157.79 | +26.75% | 29 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 | $61.33 | +46.75% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $59 → $65 | $47.72 | +36.21% | 28 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $98 | $87.05 | +12.58% | 5 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $180 | $149.61 | +20.31% | 2 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $3.79 | +269.39% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $885 → $890 | $852.03 | +4.46% | 35 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $442.84 | -20.96% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $980 → $1,008 | $1,055.37 | -4.49% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $46 | $58.53 | -21.41% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $35 | $18.54 | +88.78% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $42 | $31.05 | +35.27% | 6 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $14.09 | +41.94% | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $71.93 | n/a | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $398 → $502 | $546.93 | n/a | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 → $96 | $135.07 | n/a | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $138 | $151.64 | n/a | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $9.59 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $68 | $67.66 | n/a | 13 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $183 | $245.57 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.5 | $3.77 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $18.51 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $2.15 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.09 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.46 | n/a | 2 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9 | $37.49 | n/a | 1 | Jul 19, 2019 |
argenx SE
Sep 3, 2026
Maintained: Buy
Price Target: n/a
Current: $912.60
Upside: -
Eli Lilly and Company
Sep 1, 2026
Maintained: Buy
Price Target: $1,350 → $1,440
Current: $1,160.08
Upside: +24.13%
Latigo Biotherapeutics
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $21.77
Upside: +129.67%
BioMarin Pharmaceutical
Aug 31, 2026
Maintained: Buy
Price Target: $104 → $105
Current: $66.97
Upside: +56.79%
BioNTech SE
Aug 20, 2026
Maintained: Buy
Price Target: $138
Current: $103.81
Upside: +32.94%
Vertex Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $610 → $633
Current: $556.75
Upside: +13.70%
Damora Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $50
Current: $28.18
Upside: +77.43%
Jade Biosciences
Aug 11, 2026
Maintained: Buy
Price Target: $40 → $48
Current: $21.40
Upside: +124.30%
Pfizer
Aug 5, 2026
Maintained: Buy
Price Target: $34
Current: $29.02
Upside: +17.16%
Neurocrine Biosciences
Jul 30, 2026
Maintained: Buy
Price Target: $200
Current: $157.79
Upside: +26.75%
Jul 15, 2026
Maintained: Buy
Price Target: $90
Current: $61.33
Upside: +46.75%
Jul 9, 2026
Maintained: Buy
Price Target: $59 → $65
Current: $47.72
Upside: +36.21%
Jun 30, 2026
Maintained: Buy
Price Target: $98
Current: $87.05
Upside: +12.58%
May 22, 2026
Maintained: Buy
Price Target: $180
Current: $149.61
Upside: +20.31%
Apr 30, 2026
Maintained: Buy
Price Target: $14
Current: $3.79
Upside: +269.39%
Mar 11, 2026
Maintained: Buy
Price Target: $885 → $890
Current: $852.03
Upside: +4.46%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $442.84
Upside: -20.96%
Feb 19, 2026
Maintained: Buy
Price Target: $980 → $1,008
Current: $1,055.37
Upside: -4.49%
Dec 11, 2025
Maintained: Buy
Price Target: $50 → $46
Current: $58.53
Upside: -21.41%
Dec 5, 2025
Maintained: Buy
Price Target: $26 → $35
Current: $18.54
Upside: +88.78%
Nov 17, 2025
Maintained: Buy
Price Target: $13 → $42
Current: $31.05
Upside: +35.27%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $14.09
Upside: +41.94%
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $71.93
Upside: n/a
Aug 12, 2025
Maintained: Buy
Price Target: $398 → $502
Current: $546.93
Upside: n/a
Jul 8, 2025
Maintained: Buy
Price Target: $86 → $96
Current: $135.07
Upside: n/a
Jun 18, 2025
Maintained: Buy
Price Target: $138
Current: $151.64
Upside: n/a
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $9.59
Upside: n/a
Apr 23, 2025
Maintained: Buy
Price Target: $70 → $68
Current: $67.66
Upside: n/a
Apr 1, 2025
Maintained: Buy
Price Target: $183
Current: $245.57
Upside: n/a
Jan 29, 2025
Maintained: Hold
Price Target: $6 → $2.5
Current: $3.77
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $18.51
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $2.15
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $17.09
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $9.46
Upside: n/a
Jul 19, 2019
Initiated Coverage: Hold
Price Target: $9
Current: $37.49
Upside: n/a